Objective: To determine the prognostic utility of tauopathy-associated single nucleotide polymorphisms (SNPs) in sporadic behavioral-variant frontotemporal dementia (bvFTD).
Significant heterogeneity exists in the natural history of behavioral-variant frontotemporal dementia (bvFTD), the most common clinical phenotype in frontotemporal lobar degeneration (FTLD) spectrum pathology. Approximately equal numbers of cases appear to be attributable to the 2 main broad categories of proteinopathies 1,2 : those containing pathologic aggregations of the microtubule-associated protein, tau (i.e., FTLD-tau), 3 and those with inclusions composed of the RNA-binding protein, TDP-43 (i.e., FTLD-TDP). 3 Prognostic markers are critical for clinical care and for disease-modifying clinical trials targeting these abnormal proteinaceous aggregates. 4 Studies of survival between FTLD-tau and FTLD-TDP have been inconsistent. [5] [6] [7] [8] [9] While the signs of clinical amyotrophic lateral sclerosis (FTD-ALS) are a reasonably reliable Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
marker for underlying TDP-43 pathology and shorter survival in bvFTD, 2, 9 prognostic information related to the presence of tau pathology in bvFTD is unknown.
A recent case-control, genome-wide association study of autopsy-proven cases identified risk alleles in rs1768208 (myelin-associated oligodendrocyte basic protein [MOBP] , OMIM600948) and rs8070723 (microtubule-associated protein tau [MAPT] , OMIM157140) associated with progressive supranuclear palsy (PSP), a form of FTLD-tau. 10 We previously found that these SNPs are associated with FTLD-tau compared with FTLD-TDP, and correlated with neuroanatomical gray matter (GM) and white matter (WM) degeneration on MRI. 11 This study did not constrain analyses by FTLD clinical phenotype and did not examine disease duration. Here, we examined the prognostic correlates for MOBP rs1768208 and MAPT rs8070723 genotype in the most common FTLD phenotype, sporadic bvFTD. Our findings suggest that rs1768208 risk allele in MOBP is associated with a shorter disease course, and that this may be related to worse WM disease.
METHODS Subjects. Patients included for study were seen at the Penn Frontotemporal Degeneration Center or Alzheimer's Disease Center. The target population for study was sporadic patients with a clinical diagnosis of bvFTD and underlying FTLD neuropathology (i.e., FTLD-tau or FTLD-TDP) without ALS. To confirm that all cases met current clinical criteria, 1 charts were retrospectively reviewed by separate investigators (D.J.I., C.T.M., K.R., J.B.T.) and discussed at consensus meetings. All cases who met "probable" bvFTD criteria had CSF samples obtained during routine diagnostic lumbar puncture and were screened for levels of Alzheimer disease (AD)-associated analytes (i.e., b-amyloid, total tau, and phosphorylated tau), as previously described. 12 All of the probable bvFTD cases in this cohort have a total tau/ b-amyloid ratio that is not suggestive of an autopsy-confirmed AD profile (i.e., ,0.34), 12 minimizing the possible inclusion of atypical AD cases that can influence clinically derived FTLD cohorts. 13, 14 In a subset of patients followed to autopsy (i.e., "definite" bvFTD), neuropathologic examination was performed as previously described 15 using well-established monoclonal antibodies and current neuropathologic criteria (table 1) . 3 The final cohort included 81 patients who met probable or definite bvFTD criteria. 1 We further constrained our bvFTD sample to presumed sporadic cases because SNPs may potentially have specific associations in hereditary cases, 16 and hereditary cases may also have different rates of survival. 8 A validated pedigree analysis 17 was performed to assess family history and found 33 cases (40.7%) classified as "low" risk or "apparent sporadic" and only 6 (7.4%) as "medium" risk and 3 (3.7%) with a "high" risk score for hereditary disease. The remaining 39 cases (48.1%) had insufficient clinical data for comprehensive pedigree analysis. As such, we performed full genotyping for the 3 major molecular etiologies of hereditary FTLD in all living cases (i.e., GRN: OMIM138945; MAPT: OMIM157140; C9orf72: OMIM614260) as described, [18] [19] [20] which account for the vast majority of hereditary FTLD, 17 and excluded all cases with known pathogenic mutations in these genes. Retrospective genotyping in autopsyconfirmed cases targeted only genes associated with the neuropathologic diagnosis (i.e., GRN and C9orf72 for FTLD-TDP and MAPT for FTLD-tau). 3 Further, 6 of the "medium" and "high" score cases were additionally genotyped and were negative for mutations in 43 genes with known associations to neurodegenerative disease. Thus, participants in this cohort have a high likelihood of sporadic disease.
Standard protocol approvals, registrations, and patient consents. All procedures, including DNA and CSF collection and autopsy, required informed consent and were performed in accordance with the rules of the institutional review board at Penn. SNP genotyping. DNA was extracted from peripheral blood samples or brain tissue using the manufacturer's protocol (FlexiGene; Qiagen, Valencia, CA) or Quick-Gene DNA whole blood kit (AutoGen, Holliston, MA). Genotyping for rs1768208 and rs8070723 was performed using a matrix-assisted laser desorption/ionization time-of-flight spectroscopy SNP genotyping technology (MassArray; Sequenom, San Diego, CA) as previously described.
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MRI analysis. A subset of the cohort (n 5 37) and 31 healthy elderly controls (table e-1 on the Neurology ® Web site at Neurology.org) underwent structural T1-weighted MRI and diffusion-weighted imaging. Twenty-eight patients with bvFTD were included as a subset of a previously reported cohort that contained clinically heterogeneous samples and different statistical measures. 11 We measured GM density (GMD), fractional anisotropy (FA), and radial diffusion (RD). Neuroimaging analyses were performed as previously reported, 21 using nonparametric permutation analysis with 10,000 permutations. GMD was restricted to voxels containing GM using an explicit mask generated from the average GM probability map of all subjects. FA and RD were restricted using an explicit mask (FA $0.25) to constrain comparisons to regions of high probability WM. Clusters were accepted that survived an extent threshold of 50 voxels (GMD) or 200 voxels (FA/RD). We used a height threshold of p , 0.05 with family-wise error correction for multiple comparisons in patient vs control analyses and a height threshold of p , 0.01 for direct comparisons between bvFTD rs1768208 risk allele carriers and noncarriers. For further details, see appendix e-1.
Statistical analysis. Clinical data, including dates and ages at onset and death, were obtained from the Penn Integrated Neurodegenerative Disease Database, 15 and disease duration was calculated from these values and reported in years. Clinical variables were evaluated for normality using a Kolmogorov-Smirnov test and because of a nonnormal distribution analyzed with MannWhitney U tests. SNP genotypes were coded for the presence of one or more polymorphism alleles (i.e., MOBP RA1, MAPT PA1) and zero polymorphism alleles (i.e., MOBP RA2, MAPT PA2) and analyzed in a dominant model. Risk allele carrier frequencies and other categorical variables were compared using a 2 3 2 contingency table with x 2 analysis. Clinical data are reported as median with interquartile range. All analyses were 2-sided with a 5 0.05, and we did not correct for multiple comparisons because of our a priori hypotheses. Statistical analyses were performed with SPSS version 21.0 (IBM Corp., Armonk, NY).
RESULTS Risk alleles in patient groups. The presence of one or more copies of MOBP rs1768208 risk allele (T) (i.e., MOBP RA1) is marginally associated with an increased risk of FTLD-tau, 10, 11 and there was an increased frequency of MOBP RA1 patients (CT/ TT) in FTLD-tau (13/20) figure 1D) .
We assessed the specificity of the disease-duration effect associated with the MOBP rs1768208 risk allele by assessing the MAPT rs8070723 protective allele. We found that MAPT PA1 (GG/GA) patients had an earlier age at onset compared with those without this genotype (i.e., MAPT PA2; AA: U 5 3.0, p , 0.01; table 2). However, there was no effect on age at death (U 5 1.0, p . 0.1) or disease duration associated with MAPT PA1 (U 5 0.9, p . 0.1). Univariate analyses found no difference between MAPT PA1 and MAPT PA2 patient groups for sex, rs1768208 genotype, or Mini-Mental State Examination score at first visit (all p . 0.1), suggesting an independent association of MAPT PA1 with age at onset. Neuropathologic subgroup analyses for rs8070723 were limited by the small number of risk allele carriers in FTLD-tau and FTLD-TDP (table 1) .
Neuroimaging analyses. We examined the relationship of rs1768208 genotype with MRI measures of GMD and WM integrity (RD and FA) in a subset of patients with available neuroimaging data (n 5 37). Patient groups and controls had similar demographics (p . 0.1; table e-1). GMD was significantly reduced across multiple frontal and temporal cortical regions in both MOBP RA1 and MOBP RA2 patients compared with healthy elderly controls, consistent with bvFTD 22 (table e-2, figure e-1). RD was increased and FA was reduced in both MOBP RA1 and MOBP RA2 patients compared with controls in several frontal and temporal subcortical association and commissural tracts (table e-2, figure e-1).
Direct comparison of MOBP RA1 patients with MOBP RA2 patients found reduced FA in left superior corona radiata (SCR), right superior longitudinal fasciculus (SLF), and left inferior longitudinal fasciculus (ILF) ( figure 2A, table 3) , and increased RD in the left midbrain and left SCR ( figure 2B, table 3 ). There were 2 small clusters (i.e., 50-70 voxels) of significantly increased FA in the midbrain that approached significance (p , 0.05; data not shown). Direct comparison of MOBP RA1 and MOBP RA2 patient groups found reduced GMD in the right superior temporal gyrus (STG) and precuneus ( figure 2C, table 3 ).
DISCUSSION Herein, we describe the prognostic value of tauopathy-associated SNPs in a wellcharacterized cohort of patients with sporadic bvFTD. Specifically, we found shorter disease duration and age at death in MOBP RA1 (CT/TT) patients in the total cohort. This effect was confirmed in the subgroup of autopsied patients with FTLD-tau pathology. Furthermore, we found WM neurodegeneration in the midbrain, SCR, SLF, and ILF as well as significant GM atrophy in the STG and precuneus associated with rs1768208 MOBP risk allele carriers in direct comparison with MOBP RA2 cases, suggesting that this risk allele is associated with more severe neurodegeneration. In contrast, we found decreased age at onset in MAPT PA1 (GG/GA) patients but no effect for disease duration, emphasizing the specificity of the diseaseduration effect associated with the rs1768208 MOBP risk allele in bvFTD patients with FTLD-tau.
Overall median disease duration for our cohort (table 1) was similar to previous autopsy-confirmed reports for bvFTD 1,6-9 of approximately 6 to 9 years from onset of symptoms, suggesting that our cohort is representative of bvFTD. While previous studies have suggested differences in disease duration depending on FTLD-tau or FTLD-TDP pathology, it is unlikely that this is contributing to our observation of a shorter disease course in association with the T risk allele of rs1768208 in MOBP. Some authors have reported similar disease durations in bvFTD with underlying FTLD-tau and FTLD-TDP pathology, 5, 7 while others have found a longer disease duration in FTLD-tau, 9 and our group previously demonstrated a worse prognosis in FTLD-tau. 23 These discrepancies may be explained in part by inclusion of hereditary cases. There were also differences in clinical criteria used across studies, with known effects of clinical phenotypes included in some studies. For example, ALS associated with FTLD-TDP pathology has shorter survival, 9, 24 and FTLD motor phenotypes such as PSP and corticobasal syndrome may have shorter survival than other forms of FTLD-tau. 6, 8 In the present study, the bvFTD phenotype was not associated with a motor disorder that could have biased survival, and FTLD-tau and FTLD-TDP autopsy subgroups did not differ in disease duration ( figure  1D ). Thus, reduced disease duration in patients with MOBP RA1 bvFTD does not appear to be biased by a motor phenotype or the association of the MOBP risk allele with FTLD-tau pathology in our cohort.
Several observations are consistent with the possibility that the MOBP risk allele is associated with more aggressive underlying neuropathology, and in particular, significant WM disease. In addition to finding that poor prognosis in clinically diagnosed bvFTD is associated with the T risk allele of rs1768208 in MOBP, examination of autopsy subgroups demonstrated shorter disease duration in T allele carriers with FTLD-tau pathology (figure 1B). We did not find a similar effect for MOBP RA1 in the FTLD-TDP subgroup ( figure 1C) . The association of rs1768208 SNP in MOBP with autopsy-proven PSP was identified in a case-control, genome-wide association study, 10 and we previously demonstrated that this risk allele is associated with an increased likelihood of all forms of FTLD-tau in direct comparison with FTLD-TDP. 11 MOBP is a major component of myelin associated exclusively with oligodendrocytes, and may serve to stabilize myelin in times of oxidative stress or myelin turnover. 25 The MOBP gene involves alternative splicing to form several different protein isoforms, and the rs1768208 locus is situated in an intronic region between exons 1 and 2 (NC_000003.11: g.39523003T.C, NM_182935.2:c.2511389T.C). From this perspective, it is tempting to hypothesize that the risk polymorphism could alter gene splicing/function to exacerbate myelin-associated degeneration in the setting of WM pathology found in FTLD-tau, 26, 27 although the exact locus conferring disease risk for tauopathies marked by this SNP is currently unclear. Indeed, PSP and other forms of FTLD-tau have significant WM oligodendritic pathology 28, 29 that is more prominent than in FTLD-TDP. [30] [31] [32] While animal-and cell-model experiments are needed to clarify the normal function of MOBP and the association of the rs1768208 polymorphism with neurodegeneration in FTLD, our neuroimaging findings are consistent with the possibility that degeneration particularly involving WM myelin may be contributing to poorer prognosis in MOBP RA1 patients. Specifically, we found increased RD in the WM of the midbrain and SCR, and additional decrease in FA in the SLF and ILF ( figure 2, A and B) in MOBP RA1 patients. These are areas of known WM degeneration in tauopathies such as PSP. 28 Moreover, increased RD is associated with reduced myelin integrity. 33 Thus, it is possible that the observed reduced disease duration reflects an association of MOBP RA1 with a more malignant subtype of FTLD-tau, which compromises WM myelin. We previously demonstrated that WM disease in these regions is a robust marker of FTLD-tau pathology, 32 and others found that brainstem hypometabolism conferred worse prognosis in nonautopsy-confirmed bvFTD. 34 MOBP rs1768208 risk allele carriers also had more severe GM atrophy in STG and parietal lobe (precuneus). These areas are implicated in both FTLDtau and FTLD-TDP. 22, 32, 35, 36 We previously found that lower copy numbers of rs1768208 MOBP risk allele are associated with reduced FA in SLF in a clinically mixed cohort; however, this was in a more posterior and superior region than in the current study of sporadic bvFTD. 11 Additional work is needed to further investigate these imaging findings. These results suggest that the rs1768208 polymorphism appears to affect WM degeneration in FTLD-tau more than FTLD-TDP. The small number of carriers in the FTLD-TDP subgroup in this study precluded quantitative analyses of this finding.
We found that the protective allele marking the H2 haplotype in rs8070723 had no effect on disease duration. Therefore, these results suggest that the association of reduced disease duration with rs1768208 in MOBP for bvFTD is specific for this risk allele. Carriers of the G protective allele in rs8070723 nevertheless had an earlier age at onset by a median of 3.5 years (table 1) . Others have found similar results of earlier age at onset for H2 carriers by 5 years in a clinically mixed FTLD cohort without autopsy confirmation. 37 The H1 and H2 haplotypes comprise inverted sequences of polymorphisms in linkage disequilibrium in the region on chromosome 17 coding MAPT, and the H1 haplotype is overrepresented in forms of FTLD-tau. 38, 39 Cases with FTLD-tau have been reported to have an older age at onset. 9 Thus, the observed association of an older age at onset in MAPT PA2 patients could reflect differences in the natural history of patients with bvFTD who have underlying FTLD-tau compared with FTLD-TDP. The low frequency of the protective allele in both neuropathologic subgroups limited clarification of this association in the current study, and additional work is needed in a larger sample with autopsy-proven disease.
Several caveats should be kept in mind when interpreting the results. First, this was a small, highly educated, and largely Caucasian cohort from a tertiary academic center, which has inherent referral bias, and a population-based approach is required for generalizability and further elucidation of genotype frequencies across racial groups, but publically available samples for such analyses do not yet exist. Our neuroimaging cohort consisted largely of living cases (table e-1), therefore we cannot confirm prognostic associations of neuroimaging findings in sporadic bvFTD with direct assessment of pathology. Finally, although direct comparisons within the patient groups were robust and supported our survival observations with rs1768208, we did not assess genotype in the control group for neuroimaging analyses, so we cannot exclude the possibility that genetic makeup of controls influenced our imaging results. With these caveats in mind, the risk polymorphism at rs1768208 in MOBP may confer a worse prognosis in patients with bvFTD, and this may be related to more severe neurodegeneration particularly in subcortical WM. Tauopathy-associated SNPs thus may provide a promising candidate for prognostic biomarkers in bvFTD. Prospective studies utilizing emerging biomarkers for FTLD-tau 40 will be helpful to confirm these observations in a larger bvFTD cohort with known pathology. 
